Is TherapeuticsMD, Inc. overvalued or undervalued?

As of 12 November 2024, TherapeuticsMD, Inc. has moved from a grade of "does not qualify" to "risky." The company is currently considered overvalued based on its financial metrics. Key ratios include a Price to Book Value of 0.54, an EV to EBIT of -3.11, and an EV to EBITDA of -3.66, indicating significant financial distress and inefficiency.
When compared to peers, TherapeuticsMD's P/E ratio is -12.96, while ASP Isotopes, Inc. has a P/E of -24.01, and Journey Medical Corp. stands at -15.59, all reflecting a challenging environment for these companies. The negative return of -42.19% over the past year, compared to a 10.26% gain in the S&P 500, further underscores the company's struggles in the market.